YOLFTbeta
SyntekaBio Inc

SyntekaBio Inc

226330 · KQ · Healthcare / Health Information Services

992.00KRW-13.00 (-1.29%)

Price History

Full chart

Market Stats

Previous Close1,005.00
Open1,011.00
Day Range991.00 – 1,053.00
52-Week Range976.00 – 6,750.00
Volume70.84K
Market Cap30.83B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.37
50-Day Avg1,363.50
200-Day Avg2,584.75

About

SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, disease susceptibility, immune typing, pharmacogenomic typing, and multi-omics information-based drug side effect prediction technology. The company was founded in 2009 and is headquartered in Daejeon, South Korea.

Company Details

  • SectorHealthcare
  • IndustryHealth Information Services
  • CEOJong Sun Jung
  • Employees52
  • Headquarters1903, 1, Expo Tower, Daejeon, South Korea, Korea
  • Websitehttps://www.syntekabio.com

Leadership

  • Jong Sun JungChief Executive Officer
  • Mr. Jongsun JungPresident & CTO
  • Mr. Brian NohChief Marketing Officer and Vice President of Strategy & Marketing
  • Mr. Joonhyuk ChoiHead of US Operations

Financials

Income Statement

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue43.48M286.58M461.37M609.68M316.66M243.99M123.41M120.89M3.43B
Growth (%)-+559.04%+60.99%+32.14%-48.06%-22.95%-49.42%-2.04%+2736.72%
Gross Profit--478.51M609.68M316.66M243.99M123.41M120.89M3.43B
Gross Margin--103.71%100.00%100.00%100.00%100.00%100.00%100.00%
Operating Expense--5.67B7.71B9.18B12.03B13.07B14.55B14.19B
Operating Income-5.81B3.60B-5.19B-7.10B-8.87B-11.79B-12.95B-14.43B-10.76B
Operating Margin-13357.81%1256.94%-1125.80%-1164.17%-2799.97%-4831.09%-10494.95%-11937.86%-313.91%
EBITDA------1.78B-9.26B-2.95B-12.51B
EBITDA Margin------730.45%-7503.62%-2440.59%-364.90%
Net Income-5.78B3.75B-22.97B-6.49B-14.80B-4.51B-11.40B-7.21B-17.38B
Net Income Margin-13302.49%1307.34%-4977.80%-1064.13%-4674.69%-1846.96%-9235.91%-5966.88%-506.76%
R&D--1.65B2.11B3.10B3.18B3.22B2.94B2.29B
R&D as % of Total Revenue--358.03%345.72%979.20%1301.97%2613.20%2429.87%66.79%
Interest Expense0059.78M84.36M254.17M1.25B375.74M2.01B2.84B
Interest Expense % of Total Revenue0.00%0.00%12.96%13.84%80.27%512.81%304.48%1661.38%82.85%

Balance Sheet

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.50B12.11B47.95B44.78B67.88B55.69B52.92B43.71B46.53B
Total Liabilities5.29B10.47B1.84B3.24B40.25B24.23B21.69B18.77B14.76B
Total Equity-2.79B1.64B46.11B41.54B27.63B31.46B31.23B24.94B31.78B
Cash239.00K119.00K17.22B2.65B13.71B35.34B19.67B12.07B16.35B
Total Debt--150.23M552.24M-----

Cash Flow

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.49B-2.37B-3.28B-4.67B-6.04B-8.51B-8.08B-10.51B-10.65B
Investing Cash Flow1.52B-9.46B-19.01B-11.39B-8.10B30.23B-9.43B-5.80B-
Financing Cash Flow999.18M12.15B39.12B1.49B25.21B-89.03M1.78B8.53B-
Capital Expenditure67.67M651.05M840.68M788.88M7.48B8.76B9.43B5.82B83.11M
Free Cash Flow----5.55B-13.59B-17.27B-17.51B-16.33B-10.73B
FCF to OCF---118.99%224.96%202.89%216.73%155.35%100.78%

Earnings

Report DateDec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Mar 19, 2026May 15, 2026Aug 18, 2026
EPS Estimate---------------------------
EPS Actual-87.82-81.84-105.91-97.39-123.97-116.90-105.42-144.52-551.10-44.33197.32-166.14-265.57-182.70-81.36352.50-736.80-53.41-57.06-145.57-498.76-399.53-206.77-126.19-239.24-143.95-90.87
Surprise---------------------------
Timing---------------------------

Key Statistics & Ratios

Market Cap30.83B
Enterprise Value30.19B
Trailing P/E0.00
Forward P/E0.00
Price / Sales9.99
Price / Book1.21
Revenue (TTM)3.09B
Gross Profit (TTM)3.08B
EBITDA-8.59B
Profit Margin0.00%
Operating Margin-483.55%
Return on Equity-59.96%
Return on Assets-16.67%
Shares Outstanding24.26M
Shares Float20.13M
Beta0.37
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Nov 6, 20252664:2227